Advertisement

Conduction system abnormalities in patients with obstructive hypertrophic cardiomyopathy following septal reduction interventions

      Abstract

      We observed the impact of percutaneous transluminal septal myocardial ablation (PTSMA) and myectomy on the conduction system in patients with obstructive hypertrophic cardiomyopathy (HC). Septal reduction intervention is capable of eliminating the left ventricular outflow tract obstruction in patients with obstructive HC; however, conduction system abnormalities are frequent consequences of these procedures. A standard 12-lead electrocardiogram and Doppler echocardiogram were obtained in 204 patients who underwent PTSMA (n = 70) or myectomy (n = 134) before and at average of 3 months after intervention. Of 146 patients who had normal conduction systems before intervention, the duration of the QRS complex was significantly prolonged from 98 ± 15 to 130 ± 25 ms (p <0.0001), with right bundle branch block (RBBB) developing in 62% patients after PTSMA, and from 100 ± 13 to 154 ± 20 ms (p <0.0001), with left bundle branch block (LBBB) developing in 93% patients after myectomy. No significant difference in the QRS duration was found in the remaining 58 patients who had preexisting conduction abnormalities after intervention. In 174 patients without a preexisting permanent pacemaker, a pacemaker was implanted in 22% versus 13% of patients who underwent PTSMA (overall and without preexisting conduction block, respectively) and 10% versus 2% of patients with myectomy. The duration of baseline QRS was an independent predictor for the requirement of a permanent pacemaker (p <0.0001). Thus, RBBB often develops after PTSMA and LBBB is very frequently produced by myectomy. A possible requirement of a permanent pacemaker should always be considered before intervention when patients have preexisting RBBB or LBBB.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • McCully R.B.
        • Nishimura R.A.
        • Tajik A.J.
        • Schaff H.V.
        • Danielson G.K.
        Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy.
        Circulation. 1996; 94: 467-471
        • Schulte H.D.
        • Borisov K.
        • Gams E.
        • Gramsch-Zabel H.
        • Losse B.
        • Schwartzkopff B.
        Management of symptomatic hypertrophic obstructive cardiomyopathy-long-term results after surgical therapy.
        Thorac & Cardiovasc Surg. 1999; 47: 213-218
        • Merrill W.H.
        • Friesinger G.C.
        • Graham Jr, T.P.
        • Byrd III, B.F.
        • Drinkwater Jr., D.C.
        • Christian K.G.
        • Bender Jr, H.W.
        Long-lasting improvement after septal myectomy for hypertrophic obstructive cardiomyopathy.
        Ann Thorac Surg. 2000; 69: 1732-1735
        • Heric B.
        • Lytle B.W.
        • Miller D.P.
        • Rosenkranz E.R.
        • Lever H.M.
        • Cosgrove D.M.
        Surgical management of hypertrophic obstructive cardiomyopathy. Early and late results.
        J Thorac Cardiovasc Surg. 1995; 110: 195-206
        • Seggewiss H.
        • Gleichmann U.
        • Faber L.
        • Fassbender D.
        • Schmidt H.K.
        • Strick S.
        Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy.
        J Am Coll Cardiol. 1998; 31: 252-258
        • Sigwart U.
        Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy.
        Lancet. 1995; 346: 211-214
        • Knight C.
        • Kurbaan A.S.
        • Seggewiss H.
        • Henein M.
        • Gunning M.
        • Harrington D.
        • Fassbender D.
        • Gleichmann U.
        • Sigwart U.
        Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy.
        Circulation. 1997; 95: 2075-2081
        • Lakkis N.M.
        • Nagueh S.F.
        • Dunn J.K.
        • Killip D.
        • Spencer III, W.H.
        Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy.
        J Am Coll Cardiol. 2000; 36: 852-855
        • Spirito P.
        • Maron B.J.
        Perspectives on the role of new treatment strategies in hypertrophic obstructive cardiomyopathy.
        J Am Coll Cardiol. 1999; 33: 1071-1075
        • Seggewiss H.
        Percutaneous transluminal septal myocardial ablation.
        Eur Heart J. 2000; 21: 704-707
        • Seggewiss H.
        • Faber L.
        • Ziemssen P.
        Alcohol septal ablation for hypertrophic obstructive cardiomyopathy.
        Cardiol Rev. 1999; 7: 316-323
        • Sasson Z.
        • Yock P.G.
        • Hatle L.K.
        • Alderman E.L.
        • Popp R.L.
        Doppler echocardiographic determination of the pressure gradient in hypertrophic cardiomyopathy.
        J Am Coll Cardiol. 1988; 11: 752-756
        • Wagner G.S.
        Marriott's Practical Electrocardiography.
        9th Ed. Williams & Wilkins, Baltimore, MD1994 (86–95)
        • Henein M.Y.
        • O'Sullivan C.A.
        • Ramzy I.S.
        • Sigwart U.
        • Gibson D.G.
        Electromechanical left ventricular behavior after nonsurgical septal reduction in patients with hypertrophic obstructive cardiomyopathy.
        J Am Coll Cardiol. 1999; 34: 1117-1122
        • Kazmierczak J.
        • Kornacewicz-Jach Z.
        • Kisly M.
        • Gil R.
        • Wojtarowicz A.
        Electrocardiographic changes after alcohol septal ablation in hypertrophic obstructive cardiomyopathy.
        Heart. 1998; 80: 257-262
        • Gietzen F.H.
        • Leuner C.J.
        • Raute-Kreinsen U.
        • Dellmann A.
        • Hegselmann J.
        • Strunk-Mueller C.
        • Kuhn H.J.
        Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy.
        Eur Heart J. 1999; 20: 1342-1354
        • Nagueh S.F.
        • Lakkis N.M.
        • He Z.X.
        • Middleton K.J.
        • Killip D.
        • Zoghbi W.A.
        • Quinones M.A.
        • Roberts R.
        • Verani M.S.
        • Kleiman N.S.
        • Spencer III, W.H.
        Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy.
        J Am Coll Cardiol. 1998; 32: 225-229
        • Seggewiss H.
        • Faber L.
        • Gleichmann U.
        Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy.
        Thorac Cardiovasc Surg. 1999; 47: 94-100
        • Runquist L.H.
        • Nielsen C.D.
        • Killip D.
        • Gazes P.
        • Spencer III, W.H.
        Electrocardiographic findings after alcohol septal ablation therapy for obstructive hypertrophic cardiomyopathy.
        Am J Cardiol. 2002; 90: 1020-1022
        • Singh M.
        • Edwards W.D.
        • Holmes Jr., D.R.
        • TajiK A.J.
        • Nishimura R.A.
        Anatomy of the first septal perforating artery.
        Mayo Clin Proc. 2001; 76: 799-802
        • Lakkis N.M.
        • Nagueh S.F.
        • Kleiman N.S.
        • Killip D.
        • He Z.X.
        • Verani M.S.
        • Roberts R.
        • Spencer III, W.H.
        Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy.
        Circulation. 1998; 98: 1750-1755
        • Brunner-La Schonbeck M.H.
        • Rocca H.P.
        • Vogt P.R.
        • Lachat M.L.
        • Jenni R.
        • Hess O.M.
        • Turina M.I.
        Long-term follow-up in hypertrophic obstructive cardiomyopathy after septal myectomy.
        Ann Thorac Surg. 1998; 65: 1207-1214
        • Robbins R.C.
        • Stinson E.B.
        Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy.
        J Thorac Cardiovasc Surg. 1996; 111: 586-594
        • Faber L.
        • Seggewiss H.
        • Gleichmann U.
        Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy.
        Circulation. 1998; 98: 2415-2421
        • Chang S.M.
        • Nagueh S.F.
        • Spencer III, W.H.
        • Lakkis N.M.
        Complete heart block.
        J Am Coll Cardiol. 2003; 42: 296-300
        • Maron B.J.
        • Merrill W.H.
        • Freier P.A.
        • Kent K.M.
        • Epstein S.E.
        • Morrow A.G.
        Long-term clinical course and symptomatic status of patients after operation for hypertrophic subaortic stenosis.
        Circulation. 1978; 57: 1205-1213